Ingevity Management
Management criteria checks 1/4
Ingevity's CEO is Dave Li, appointed in Apr 2025, has a tenure of 1.42 years. total yearly compensation is $12.84M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $64.62K. The average tenure of the management team and the board of directors is 1.1 years and 4.2 years respectively.
Key information
Dave Li
Chief executive officer
US$12.8m
Total compensation
| CEO salary percentage | 6.31% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.003% |
| Management average tenure | 1.1yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Seeking Alpha • Aug 28
Ingevity: Portfolio Simplification Reveals A High-Margin Regulatory Compounder
Summary Ingevity is transforming into a focused, high-margin regulatory compounder, emphasizing Performance Materials and Pavement Technologies after divesting volatile, lower-quality segments. Q2 '26 results highlight margin inflection: adjusted EBITDA rose 14% to $115M, margin expanded to 36.6%, and EPS increased to $1.74, demonstrating strong operating leverage. Hybrid vehicle adoption and infrastructure spending underpin resilient demand for NGVT’s emissions-control and pavement solutions, while PFAS filtration offers incremental EBITDA growth optionality. NGVT trades at a discount on EV/EBITDA versus peers, but improved business quality and robust free cash flow support a bullish outlook despite EV transition and leverage risks. Read the full article on Seeking AlphaAnalysis Article • Aug 07
Ingevity (NYSE:NGVT) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Ingevity Corporation's ( NYSE:NGVT ) solid earnings announcement recently didn't do much to the stock price. We did...
Narrative Update • Jul 04
NGVT: Share Repurchases And 2026 Guidance Will Support Future P/E Rerating
Analysts have modestly raised their price target for Ingevity to $89.0 from $85.5, citing updated assumptions that include a smaller expected revenue decline, a slightly lower discount rate, and a marginally reduced profit margin and future P/E ratio. What’s in the News for Ingevity Ingevity reaffirmed full year 2026 earnings guidance, with expected net sales in a range of $1.05b to $1.15b.Analysis Article • Jun 18
Ingevity (NGVT) Stock Could Be 14% Undervalued on Its Portfolio Reshaping Narrative
Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves. See our latest analysis for Ingevity. At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building...Narrative Update • Jun 13
NGVT: Portfolio Reshaping And Buybacks Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target for Ingevity, citing largely stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their current view. What's in the News Ingevity completed the sale of its Ozark Materials Road Markings product line and divested its North Charleston CTO refinery and most of the Industrial Specialties product line, as part of a portfolio reshaping effort.Narrative Update • May 29
NGVT: Share Repurchases And Margin Strength Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target on Ingevity, citing consistent assumptions for revenue growth, profit margins, discount rate, and future P/E as the basis for their view. What's in the News From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares, representing 2.18% of its stock, for a total of $51.94 million under its ongoing buyback program announced on August 2, 2022 (Key Developments).Narrative Update • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Narrative Update • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Narrative Update • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Narrative Update • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Narrative Update • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Narrative Update • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Narrative Update • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Narrative Update • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Narrative Update • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Narrative Update • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Narrative Update • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analysis Article • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analysis Article • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Narrative Update • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analysis Article • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analysis Article • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...New Narrative • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analysis Article • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analysis Article • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analysis Article • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analysis Article • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalysis Article • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analysis Article • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$25m |
| Mar 31 2026 | n/a | n/a | -US$156m |
| Dec 31 2025 | US$13m | US$811k | -US$150m |
Compensation vs Market: Dave's total compensation ($USD12.84M) is above average for companies of similar size in the US market ($USD5.19M).
Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.
CEO
Dave Li (53 yo)
1.4yrs
Tenure
US$12,839,719
Compensation
Mr. David H. Li, also known as Dave, serves as Independent Director at Hexcel Corporation since May 8, 2025. He serves as Director of CoorsTek Inc. He served as an Independent Director at Maxeon Solar Tech...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.4yrs | US$12.84m | 0.0028% $ 64.6k | |
| Senior VP | 2.3yrs | US$1.22m | 0.046% $ 1.1m | |
| Senior VP & Chief Human Resources Officer | 2.1yrs | US$1.19m | 0.0014% $ 33.7k | |
| Senior VP & CFO | less than a year | no data | 0.048% $ 1.1m | |
| Senior Vice President of Operations | less than a year | no data | 0.026% $ 611.5k | |
| Vice President | less than a year | no data | no data | |
| Vice President of Investor Relations | less than a year | no data | no data | |
| Director of Communications | 3.3yrs | no data | 0.00065% $ 15.2k | |
| Senior VP & President of Advanced Polymer Technologies | 1.5yrs | no data | no data | |
| Senior VP & President of Performance Materials | less than a year | no data | no data |
1.1yrs
Average Tenure
51yo
Average Age
Experienced Management: NGVT's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.4yrs | US$12.84m | 0.0028% $ 64.6k | |
| Independent Director | 7.6yrs | US$240.02k | 0.0078% $ 183.5k | |
| Independent Director | 10.3yrs | US$1.07m | 0.093% $ 2.2m | |
| Independent Director | 10.3yrs | US$225.02k | 0.065% $ 1.5m | |
| Independent Director | 1.8yrs | US$240.02k | no data | |
| Independent Director | 7.6yrs | US$240.02k | 0.037% $ 856.4k | |
| Independent Director | 1.4yrs | US$202.52k | no data | |
| Independent Director | 3.6yrs | US$311.27k | no data | |
| Independent Director | 4.2yrs | US$225.02k | 0.0045% $ 105.1k |
4.2yrs
Average Tenure
61yo
Average Age
Experienced Board: NGVT's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 23:45 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ingevity Corporation is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |